Overview on Pathophysiology and Newer Approaches to Treatment of Peripheral Neuropathies

CNS Drugs

Volumn 21, Issue , 2007, Pages 3-12

  Vanotti, Alessandra ^a   Osio, Maurizio ^a   Mailland, Enrico ^a   Nascimbene, Caterina ^a   Capiluppi, Elisa ^a   Mariani, Claudio ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Diabetic Neuropathy; Gabapentin; Neuropathic Pain; Peripheral Neuropathy; Pregabalin

Indexed keywords

ADENOSINE; AMANTADINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; CANNABINOID; CARBAMAZEPINE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEXTROMETHORPHAN; GABAPENTIN; GLYCINE; ISOSORBIDE DINITRATE; KETAMINE; LAMOTRIGINE; LEVACECARNINE; LIDOCAINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PHENYTOIN; PREGABALIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; THIOCTIC ACID; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; ACETYLCARNITINE; NARCOTIC ANALGESIC AGENT; NOOTROPIC AGENT;

ANALGESIA; ANATOMICAL CONCEPTS; DIABETIC NEUROPATHY; DISEASE COURSE; DNA SYNTHESIS; DRUG MECHANISM; GENE EXPRESSION; HUMAN; INFLAMMATION; MITOCHONDRION; NERVE FIBER; NEUROPATHY; OXIDATIVE STRESS; PAIN; PATHOGENESIS; PATHOPHYSIOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SENSITIZATION; TREATMENT PLANNING; ANIMAL; CLINICAL TRIAL;

ACETYLCARNITINE; ANALGESICS, OPIOID; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NOOTROPIC AGENTS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 35348916612     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/00023210-200721001-00002     Document Type: Review

References (53)

1. IASP Task Force for Taxonomy. International Association for the Study of Pain (IASP) pain terminology. Seattle (WA): IASP, 2004
2. Wilkinson PR. Neurophysiology of pain. Part I, mechanisms of pain in the peripheral nervous system. CPD Anaesthesia 2001; 3(3): 103–8
3. Cronje RJ, Williamson OD. Is pain ever normal? Clin J Pain 2006; 22(8): 692–9
4. Empl M, Renaud S, Erne B, et al. TNFα expression in painful and nonpainful neuropathies. Neurology 2001; 56(10): 1371–7
5. Shubayev VI, Myers RR. Endoneurial remodeling by TNFα and TNFα-releasing proteases: a spatial and temporal co-localization study in painful neuropathy. J Peripher Nerv Syst 2002; 7(1): 28–36
6. Shubayev VI, Myers RR. Anterograde TNFα transport from rat dorsal root ganglion to spinal cord and injured sciatic nerve. Neurosci Lett 2002; 320(1–2): 99–101
7. Melzack R, Coderre TJ, Katz J, et al. Central neuroplasticity and pathological pain. Ann N Y Acad Sci 2001; 933: 157–74
8. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol 2003; 60(11): 1524–34
9. Zaremba PD, Bialek M, Blaszczyk B, et al. Non-epilepsy uses of antiepilepsy drugs. Pharmacol Rep 2006; 58(1): 1–12
10. MacPherson RD. The pharmacological basis of contemporary pain management. Pharmacol Ther 2000; 88(2): 163–85
11. Offenbaecher M, Ackenheil M. Current trends in neuropathic pain treatments with special reference to fibromyalgia. CNS Spectr 2005; 10(4): 285–97
12. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003; 25(10): 2506–38
13. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study. Pain 2001; 94(2): 215–24
14. Rowbotham M, Harden N, Stacey B, et al. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280(21): 1837–42
15. Field MJ, Oles RJ, Lewis AS, et al. Gabapentin (Neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol 1997; 121(8): 1513–22
16. Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 2002; 57(5): 451–62
17. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004; 63(11): 2104–10
18. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005; 6(4): 253–60
19. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110(3): 628–38
20. Atli A, Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med 2005; 6(3): 225–34
21. Tanabe M, Sakaue A, Takasu K, et al. Centrally mediated antihyperalgesic and antiallodynic effects of zonisamide following partial nerve injury in the mouse. Naunyn Schmiedebergs Arch Pharmacol 2005; 372(2): 107–14
22. Guay DR. Adjunctive agents in the management of chronic pain. Pharmacotherapy 2001; 21(9): 1070–81
23. Wolfe GI, Trivedi JR. Painful peripheral neuropathy and its nonsurgical treatment. Muscle Nerve 2004; 30(1): 3–19
24. Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J Pain Symptom Manage 2004; 27(2): 133–9
25. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine vs placebo in patients with painful diabetic neuropathy. Pain 2005; 116(1–2): 109–18
26. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med 2005; 6(5): 346–56
27. Rowbotham MC, Goli V, Kunz NR, et al. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110(3): 697–706
28. Sindrup SH, Bach FW, Madsen C, et al. Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology 2003; 60(8): 1284–9
29. Boureau F, Legallicier P, Kabir-Ahmadi M. Tramadol in postherpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain 2003; 104(1–2): 323–31
30. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology 1998; 50(6): 1842–6
31. Sindrup SH, Andersen G, Madsen C, et al. Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain 1999; 83(1): 85–90
32. Krishnan ST, Rayman G. New treatments for diabetic neuropathy: symptomatic treatments. Curr Diab Rep 2003; 3(6): 459–67
33. Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S. VR1 receptor modulators as potential drugs for neuropathic pain. Mini Rev Med Chem 2003; 3(7): 729–48
34. Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with type 2 diabetes mellitus. Diabet Med 2001; 18(3): 185–92
35. Allie D, Rodriguez G, Jacobs A, et al. Breakthrough medical approach in the management of patients with diabetic neuropathy: a compendium of cases studies and clinical decision making. Vasc Dis Manage 2005; Suppl Nov/Dec: 1S-9S
36. Vinik AI, Maser RE, Mitchell BD, et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26(5): 1553–79
37. Mizisin AP. Comparative neuropathology and diabetic autonomic neuropathy. Am J Pathol 2003; 163(5): 1703–6
38. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41(12): 1746–50
39. Famularo G, De Simone C, et al. HIV-1 infection and carnitine metabolism. J Immunol Immunopharmacol 1996; XVI(3–4): 70–3
40. Herzmann C, Johnson MA, Youle M. Long-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005; 6(6): 344–50
41. Cossarizza A, Mussini C, Mongiardo N, et al. Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome. AIDS 1997; 11(1): 19–26
42. Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS 1997; 11(2): 185–90
43. Ghirardi O, Lo Giudice P, Pisano C, et al. Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 2005; 25(4): 2681–7
44. Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003; 9(15): 5756–67
45. De Angelis C, Scarfo C, Falcinelli M, et al. Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve injury. Int J Clin Pharmacol Res 1992; 12(5–6): 269–79
46. Osio M, Muscia F, Zampini L, et al. Acetyl-1-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst 2006; 11(1): 72–6
47. Chiechio S, Copani A, De Petris L, et al. Transcriptional regulation of metabotropic glutamate receptor 2/3 expression by the NF-kappaB pathway in primary dorsal root ganglia neurons: a possible mechanism for the analgesic effect of L-acetylcarnitine. Mol Pain 2006; 2: 20
48. Chiechio S, Caricasole A, Barletta E, et al. L-Acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Mol Pharmacol 2002; 61(5): 989–96
49. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy: a long-term, randomised, double-blind, placebo-controlled study. Drugs R D 2002; 3(4): 223–31
50. Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28(1): 89–94
51. Hart AM, Wilson AD, Montovani C, et al. Acetyl-1-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004; 18(11): 1549–60
52. Youle M, Osio M; on behalf of the ALCAR Study Group. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl l-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007 May; 8(4): 241–50
53. Maestri A, De Pasquale Ceratti A, Cundari S, et al. A pilot study on the effect of acetyl-L-carnitine in paclitaxel- and cisplatin-induced peripheral neuropathy. Tumori 2005; 91(2): 135–8